We have not explained this story yet. The original headline, summary and link are below.

Charles River Laboratories expects adjusted earnings per share (EPS) of $2.90-$3.00 for Q3, facing challenges from lower North American research model volumes due to flat NIH budgets and slow grant processing. Despite these operational headwinds, the company plans to continue its acquisition strategy to drive future growth.